SARASOTA, Fla., Aug. 6, 2020 /PRNewswire/ -- INVO Bioscience, Inc. (OTCQB: INVO), ("the Company", "INVO") a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo Intravaginal Culture System, is scheduled to participate in a virtual presentation at the August 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, August 19, 2020 at 2:00pm ET (11:00am PT).
A webcast of the presentation will be posted under the investor relations section of INVO Bioscience website at https://www.invobioscience.com/investors/, can be accessed at https://www.webcaster4.com/Webcast/Page/2162/36418 or www.lythampartners.com/virtual. A replay of the presentation will be available following the event.
Management will also be participating in virtual one-on-one meetings on August 19-21, 2020. To arrange a meeting, please contact Robert Blum of Lytham Partners at email@example.com or visit www.lythampartners.com/virtual.
About INVO Bioscience
INVO Bioscience, Inc. (OTCQB: INVO) ("INVO") is an innovative medical device company developing solutions for the global infertility industry. INVO's goal is to increase access to care and expand fertility treatment across the globe while seeking to lower the cost and increase the availability of care. INVO's lead commercial product, the INVOcell, is a patented Assisted Reproductive Technology (ART) used in the treatment of infertility. The INVOcell device and procedure is unique as the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. As an alternative to traditional in Vitro Fertilization (IVF), the revolutionary in vivo method of vaginal incubation offers patients a more natural and intimate experience. INVO Bioscience is headquartered in Sarasota, FL. For more information, please visit http://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
Steve Shum, CEO
Lytham Partners, LLC
SOURCE INVO Bioscience, Inc.
These press releases may also interest you